Quantcast
Last updated on April 23, 2014 at 1:22 EDT

Latest Dopamine agonists Stories

2011-06-10 09:00:00

BRUSSELS, June 10, 2011 /PRNewswire/ -- Results from new post hoc analyses assessing the effects of Neupro® (rotigotine transdermal system) in Restless Legs Syndrome (RLS) and utilizing novel surrogate markers suggested improved daytime functioning and daytime symptoms, reduced RLS-related pain and improved mood and depressive symptoms in patients with moderate to severe RLS. The data were presented at the 15th International Congress of Parkinson's disease and Movement...

2011-06-09 09:00:00

BRUSSELS, June 9, 2011 /PRNewswire/ -- A post hoc analysis from the RECOVER study (Randomized Evaluation of the 24-hour Coverage: Efficacy of Rotigotine Transdermal System) suggested that patients with Parkinson's disease who used Neupro® (rotigotine transdermal system) may experience improvements in key markers of mood/cognition, such as taking interest in surroundings and getting pleasure out of life. Additional data presented from a one year open label follow-up of...

2011-06-09 08:30:00

ABBOTT PARK, Ill., June 9, 2011 /PRNewswire/ --Interim efficacy and safety results from a long-term, 54-week, Phase III open-label study of Abbott's investigational treatment for advanced Parkinson's disease showed that patients treated with levodopa-carbidopa intestinal gel (LCIG) for 12 weeks reported a decrease in "off" time and an increase in "on" time without troublesome dyskinesias. The results were reported at the International Congress of Parkinson's Disease and Movement...

2011-05-11 19:32:02

Scientists are reporting development of three promising formulations that could be used in a vaccine to treat methamphetamine addiction "” one of the most serious drug abuse problems in the U.S. The report appears in the Journal of the American Chemical Society. In the paper, Kim Janda and colleagues note that methamphetamine use and addiction cost the U.S. more than $23 billion annually due to medical and law enforcement expenses, as well as lost productivity. The drug, also called...

2011-04-14 06:00:00

BRUSSELS, April 14, 2011 /PRNewswire/ -- New 5-year data from the longest prospective open-label Restless Legs Syndrome (RLS) study to date, show that Neupro® (rotigotine) demonstrated continued symptomatic clinical benefit with a low risk of augmentation. Over the five year period, clinically significant augmentation occurred in 5.1% of patients receiving rotigotine at EU approved doses (1, 2 and 3 mg/24h) and in 13.2% of patients receiving one of the five evaluated...

2011-04-13 12:30:00

BRUSSELS, April 13, 2011 /PRNewswire/ -- New rotigotine data shown in four poster presentations at the 63rd Annual Meeting of the American Academy of Neurology (AAN) in Hawaii, U.S., highlighted the importance in Parkinson's disease (PD) of addressing both motor- and non-motor symptoms, such as sleep. The data also demonstrated the long-term efficacy and tolerability of rotigotine and showed that plasma rotigotine levels remained stable following patch removal and application of a new...

2011-04-13 07:42:03

(Ivanhoe Newswire) -- Results of the first, long-term clinical trial show the investigational drug safinamide may reduce dyskinesia (involuntary movements) in mid-to-late stage Parkinson's disease. "Our findings over a two-year treatment period suggest that taking safinamide in addition to levodopa and other dopaminergic treatments could help patients who continue to experience tremors and involuntary movement problems," study author Ravi Anand, M.D., a consultant with Newron Pharmaceuticals...

2011-04-08 15:46:05

A study of the salamander brain has led researchers at Karolinska Institutet to discover a hitherto unknown function of the neurotransmitter dopamine. In an article published in the prestigious scientific journal Cell Stem Cell they show how in acting as a kind of switch for stem cells, dopamine controls the formation of new neurons in the adult brain. Their findings may one day contribute to new treatments for neurodegenerative diseases, such as Parkinson's. The study was conducted using...

18600f84874db0ac5e451ff012118df91
2011-03-21 06:20:00

Despite Minnesota lawmakers seeking a ban on chemicals used in common synthetic drugs, revelers at a spring break party in a Minneapolis suburb overdosed this week on one of the risky substances, leaving one dead, officials told Reuters on Sunday. Iowa Rep. Sen. Charles Grassley, just two days ago proposed a similar ban on chemicals used in such synthetic drugs known as Spice and K2, a synthetic marijuana. Trevor Robinson, 19, died of an overdose at the spring break party while ten other...

2011-03-09 12:59:00

NESS ZIONA, Israel, March 9, 2011 /PRNewswire/ -- NeuroDerm, Ltd. announced today the enrollment of the first group of patients in its Phase I/II clinical trial of ND0611, a new patch for the treatment of Parkinson's disease. ND0611, a proprietary carbidopa liquid formula administered via a dermal patch, is designed to increase the bioavailability and efficacy of orally- administered levodopa and thus improve treatment of Parkinson's disease. In pre-clinical studies, plasma...